Gain expertise in physiotherapy at #EBROW25! 📅 22 Feb, 8:00–13:00📍(CICSU) or virtually Join experts to explore: 🩺Disease awareness & individualized strategies 💡 Case studies/simulations 🤝Optimizing care for #bronchiectasis patients 👉

#EBROW25 🚨 Aspiring to lead in clinical research trials? 🎓 Explore all phases of clinical research design in Bronchiectasis. 👥 Exclusively onsite! Spaces limited—don’t miss out! 👇 📅 20 Feb 2025 | ⌚ 08:30-13:30CET 📍 Sorbonne, Paris

A global survey revealed marked heterogeneity in long COVID management worldwide 

🔥🔥#Epidemiology of #Bronchiectasis 🫁 Definition and Characteristics: Bronchiectasis is characterized by chronic cough 🤧, daily sputum production 💧, and recurrent pulmonary exacerbations 🌀. It is diagnosed through a chest computed tomography (CT) scan 🖥️ that shows airway dilation 🩺. 📈 Increase in #Prevalence and #Incidence: Over the past decades 📅, there has been a global rise in bronchiectasis cases 🌍, mainly due to increased disease awareness 🧠 and improvements in imaging techniques 📸. Reported prevalence ranges from 52 to over 1000 cases per 100,000 people. 🌍 Geographical Heterogeneity: Significant differences in bronchiectasis prevalence and incidence exist across regions 🗺️, attributed to variations in disease causes, comorbidities, and access to healthcare 🚑. For instance, prevalence is higher in Asia and the UK 🇬🇧 compared to continental Europe 🇪🇺 and the U.S. 🇺🇸. 🦠 Common Causes and Comorbidities: Main causes include infections like #tuberculosis 🦠, chronic lung diseases such as #COPD 🌬️, and systemic conditions like #cysticfibrosis 🧬. Frequent comorbidities are #cardiovascular diseases ❤️, #depression 😔, and #osteoporosis 🦴. 🔬 Microbiology and Associated Factors: Chronic bacterial colonization, especially with #Pseudomonas aeruginosa 🧫 and non-tuberculous mycobacteria #NTM🧪, is linked to worse outcomes 📉, more exacerbations ⚠️, and higher healthcare costs 💰. 💸 Economic Burden: Treating bronchiectasis places a significant financial strain on healthcare systems 🏥, particularly due to frequent #hospitalizations 🏨 and #antibiotic use 💊. In the U.S., annual costs associated with bronchiectasis were $630 million higher 💵 than those without the disease. ⚰️ #Mortality: Bronchiectasis patients have a higher mortality rate ⚠️ compared to the general population 👥, although this varies by country 🌍 and patient characteristics 👨‍⚕️. Mortality rates range between 16% and 24.8% in European studies with a 4- to 5-year follow-up ⏳. 🚑 Access to Care: One of the main challenges in diagnosing and treating bronchiectasis is #unequal access to healthcare 🌐, especially in low- and middle-income countries 💡, which can lead to underestimations of prevalence and poorer disease management. 📚 This article provides a comprehensive view of bronchiectasis worldwide 🌎, highlighting regional disparities in diagnosis 🩺, treatment 💊, and clinical outcomes 📊, and emphasizes the need for further studies in underrepresented regions like #SouthAmerica 🌎 and #Africa 🌍. ▶️ @ProfJDChalmers @EvaPolverino @AlibertiStefano @OSibila @FionaMosgrove @Beika_Physio @CLDaleyMD @hayoungcc @MichalShteinbe1 @Shoemelia @AriettaSpinou @MattiaNigro23 @edo_simonetta @Lena_Group4Resp @EMBARCnetwork @PCD_UK @PcdPhysio